The evolution of type 1 diabetes

JAMA

Volumn 309, Issue 23, 2013, Pages 2491-2492

  Skyler, Jay S ^a   Sosenko, Jay M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; LEUKOCYTE ANTIGEN; PROINSULIN;

ANTIBODY TITER; DIABETES CONTROL; DISEASE ASSOCIATION; EDITORIAL; GENETIC ASSOCIATION; GENETIC RISK; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION;

EID: 84879074972     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.6286     Document Type: Editorial

References (25)

1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293-1300.
2. Pugliese A. The multiple origins of type 1 diabetes. Diabet Med. 2013;30(2):135-146.
3. Peakman M. Immunological pathways to β-cell damage in type 1 diabetes. Diabet Med. 2013;30(2):147-154.
4. Eringsmark Regnéll S, Lernmark A. The environment and the origins of islet autoimmunity and type 1 diabetes. Diabet Med. 2013;30(2):155-160.
5. Chase HP, Cuthbertson DD, Dolan LM, et al. First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J Pediatr. 2001;138(2):244-249. (Pubitemid 32156441)
6. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS; DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes. 2010;59(3):679-685.
7. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al; Diabetes Prevention Trial-Type 1 Study Group. Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2009;32(9):1603-1607.
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(suppl 1):S62-S69.
9. Greenbaum CJ, Beam CA, Boulware D, et al; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis. Diabetes. 2012;61(8):2066-2073.
10. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes. Diabetes. 2010;59(11):2846-2853.
11. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-2479.
12. Skyler JS. Primary and secondary prevention of type 1 diabetes. Diabet Med. 2013;30(2):161-169.
13. Knip M, Virtanen SM, Seppä K, et al Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of β-cell autoimmunity. N Engl J Med. 2010;363(20):1900-1908.
14. Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow's milk formula and early initiation of β-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. 2012;166(7):608-614.
15. Akerblom HK, Krischer J, Virtanen SM, et al TRIGR Study Group. The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study: recruitment, intervention and follow-up. Diabetologia. 2011;54(3):627-633.
16. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 2005;28(5):1068-1076. (Pubitemid 40616615)
17. Skyler JS; Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci. 2008;1150:190-196.
18. Skyler JS, Greenbaum CJ, Lachin JM, et al; Type 1 Diabetes TrialNet Study Group. Type 1Diabetes TrialNet - an international collaborative clinical trials network. Ann N Y Acad Sci. 2008;1150:14-24.
19. Type 1 Diabetes TrialNet. TrialNet information for healthcare professionals. http://www.diabetestrialnet.org/healthcare/index.htm. Accessed May 19, 2013.
20. Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes. 2010;59(9):2087-2093.
21. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes. 2007;8(5):286-298.
22. Sosenko JM, Krischer JP, Palmer JP, et al; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2008;31(3):528-533.
23. Sosenko JM, Skyler JS, Mahon J, et al; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Validation of the Diabetes Prevention Trial-Type 1 risk score in the TrialNet Natural History Study. Diabetes Care. 2011;34(8):1785-1787.
24. Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011;60(1):1-8.
25. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care. 2003;26(3):832-836. (Pubitemid 36929351)